Eli Lilly Signs an International Agreements with Four Diabetes Technology Companies for Connected Insulin Pen Solutions

 Eli Lilly Signs an International Agreements with Four Diabetes Technology Companies for Connected Insulin Pen Solutions

Eli Lilly to Initiate P-I Study of LY3819469 for Cardiometabolic Diseases

Shots:

  • Eli Lilly collaborates with DexCom, Glooko, myDiabby Healthcare and Roche to integrate the data and technology into connected insulin pen solutions and provide streamlined care for diabetes patients in markets outside the US
  • The 4 companies will provide diabetes management platforms that are well-suited with Lilly’s Tempo Pen and Tempo Smart Button to help streamline diabetes management through automated data collection for insulin dose tracking
  • Lilly plans to receive a CE mark for the Tempo Smart Button later in 2021 and will launch the Tempo Pen and Tempo Smart Button in various global markets following the approval

Click here to­ read full press release/ article | Ref: PRNewswire | Image: Eli Lilly

Tuba Khan

Tuba Khan is Senior Editor at PharmaShots. She is curious, creative, and passionate about recent updates and innovation in the Life sciences industry. She covers Biopharma, MedTech, and Digital health segments. Tuba also has an experience of digital and social media marketing and runs the campaigns independently. She can be contacted on tuba@pharmashots.com

Related post